Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Accumulated Expenses (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Accumulated Expenses for 3 consecutive years, with $9421.0 as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses changed N/A to $9421.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9421.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $9421.0 for FY2025, N/A changed from the prior year.
  • Accumulated Expenses hit $9421.0 in Q4 2025 for Mangoceuticals, up from $4460.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $9421.0 in Q4 2025 to a low of $2973.0 in Q2 2025.
  • Historically, Accumulated Expenses has averaged $6066.8 across 3 years, with a median of $5852.5 in 2023.
  • Biggest five-year swings in Accumulated Expenses: surged 85.42% in 2024 and later crashed 36.57% in 2025.
  • Year by year, Accumulated Expenses stood at $6595.0 in 2023, then dropped by 15.39% to $5580.0 in 2024, then surged by 68.84% to $9421.0 in 2025.
  • Business Quant data shows Accumulated Expenses for MGRX at $9421.0 in Q4 2025, $4460.0 in Q3 2025, and $2973.0 in Q2 2025.